Evidence map›Paper›PMID 27503707›Full record

ArticleJournal of controlled release : official journal of the Controlled Release Society2016

Ultrasound-guided therapeutic modulation of hepatocellular carcinoma using complementary microRNAs.

Sayan Mullick Chowdhury, Tzu-Yin Wang, Sunitha Bachawal, Rammohan Devulapally, Jung Woo Choe, Lotfi Abou Elkacem, Butrus Khuri Yakub, David S Wang, Lu Tian, Ramasamy Paulmurugan and 1 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of controlled release : official journal of the Controlled Release Society, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
3.4field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 64 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Engineering Versatile Nanomedicines for Ultrasonic Tumor Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024
    Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Ultrasound-targeted nucleic acid delivery for solid tumor therapy.Journal of controlled release : official journal of the Controlled Release Society · 2021
    Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. SARS-CoV-2 Vaccine Development: An Overview and Perspectives.ACS pharmacology & translational science · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Sayan Mullick ChowdhuryDepartment of Radiology, Molecular Imaging Program at Stanford, Stanford University School of Medicine, Stanford, CA, USA.
Tzu-Yin WangDepartment of Radiology, Molecular Imaging Program at Stanford, Stanford University School of Medicine, Stanford, CA, USA.
Sunitha BachawalDepartment of Radiology, Molecular Imaging Program at Stanford, Stanford University School of Medicine, Stanford, CA, USA.
Rammohan DevulapallyDepartment of Radiology, Molecular Imaging Program at Stanford, Stanford University School of Medicine, Stanford, CA, USA.
Jung Woo ChoeDepartment of Electrical Engineering, Stanford University Stanford, CA, USA.
Lotfi Abou ElkacemDepartment of Radiology, Molecular Imaging Program at Stanford, Stanford University School of Medicine, Stanford, CA, USA.
Butrus Khuri YakubDepartment of Electrical Engineering, Stanford University Stanford, CA, USA.
David S WangDepartment of Radiology, Molecular Imaging Program at Stanford, Stanford University School of Medicine, Stanford, CA, USA.
Lu TianDepartment of Health, Research & Policy, Stanford University, Stanford, CA, USA.
Ramasamy PaulmuruganDepartment of Radiology, Molecular Imaging Program at Stanford, Stanford University School of Medicine, Stanford, CA, USA. Electronic address: paulmur8@stanford.edu.
Jürgen K WillmannDepartment of Radiology, Molecular Imaging Program at Stanford, Stanford University School of Medicine, Stanford, CA, USA. Electronic address: willmann@stanford.edu.
Stanford University · USStanford Medicine · US

Funding

STANFORD CANCER IMAGING TRAINING (SCIT) PROGRAMT32CA009695 · NCI · STANFORD UNIVERSITY · PI BRUCE L DANIEL, Jeremy Dahl · 1993 to 2026
$7.7M
Stanford Molecular Imaging Scholars - SMISR25CA118681 · NCI · STANFORD UNIVERSITY · PI LEVIN, CRAIG S · 2006 to 2015
$5.0M
Quantification and monitoring inflammation in IBD with Molecular UltrasoundR01DK092509 · NIDDK · STANFORD UNIVERSITY · PI HARGREAVES, BRIAN ANDREW · 2012 to 2016
$2.4M
Molecular Ultrasound for Early Breast Cancer DetectionR01CA155289 · NCI · STANFORD UNIVERSITY · PI WILLMANN, JUERGEN KARL · 2011 to 2015
$1.6M
3D Passive Cavitation Imaging-Guided Therapeutic Delivery of MicroRNA into CancerR21EB022298 · NIBIB · STANFORD UNIVERSITY · PI PAULMURUGAN, RAMASAMY · 2016 to 2017
$441k
NCI NIH HHS R01 CA155289NCI NIH HHS R25 CA118681NCI NIH HHS T32 CA009695NIBIB NIH HHS R21 EB022298NIDDK NIH HHS R01 DK092509
6 · The paper itself

Abstract

Treatment options for patients with hepatocellular carcinoma (HCC) are limited, in particular in advanced and drug resistant HCC. MicroRNAs (miRNA) are non-coding small RNAs that are emerging as novel drugs for the treatment of cancer. The aim of this study was to assess treatment effects of two complementary miRNAs (sense miRNA-122, and antisense antimiR-21) encapsulated in biodegradable poly (lactic-co-glycolic acid) nanoparticles (PLGA-NP), administered by an ultrasound-guided and microbubble-enhanced delivery approach in doxorubicin-resistant and non-resistant human HCC xenografts. Proliferation and invasiveness of human HCC cells after miRNA-122/antimiR-21 and doxorubicin treatment were assessed in vitro. Confocal microscopy and qRT-PCR were used to visualize and quantitate successful intracellular miRNA-loaded PLGA-NP delivery. Up and down-regulation of miRNA downstream targets and multidrug resistance proteins and extent of apoptosis were assessed in vivo in treated human HCC xenografts in mice. Compared to single miRNA therapy, combination therapy with the two complementary miRNAs resulted in significantly (P<0.05) stronger decrease in cell proliferation, invasion, and migration of HCC cells as well as higher resensitization to doxorubicin. Ultrasound-guided delivery significantly increased in vivo miRNA-loaded PLGA-NP delivery in human HCC xenografts compared to control conditions by 5-9 fold (P<0.001). miRNA-loaded PLGA-NP were internalized in HCC cells and anti-apoptotic proteins were down regulated with apoptosis in ~27% of the tumor volume of doxorubicin-resistant human HCC after a single treatment with complementary miRNAs and doxorubicin. Thus, ultrasound-guided delivery of complementary miRNAs is highly efficient in the treatment of doxorubicin- resistant and non-resistant HCC. Further development of this new treatment approach could aid in better treatment of patients with HCC.

Indexed as

Gene Transfer TechniquesAnimalsAntagomirsAntibiotics, AntineoplasticCarcinoma, HepatocellularDoxorubicinDrug Delivery SystemsDrug Resistance, NeoplasmGenetic TherapyHep G2 CellsHumansLactic AcidLiver NeoplasmsMiceMicrobubblesMicroRNAsAntagomirsAntibiotics, AntineoplasticDoxorubicinLactic AcidMicroRNAsMIRN122 microRNA, humanMIRN21 microRNA, humanPolyglycolic AcidPolylactic Acid-Polyglycolic Acid CopolymerCancer therapyComplementary miRNADrug resistanceHepatocellular carcinomaUltrasound

Identifiers

PMID27503707
PMCPMC5185600
OpenAlexW2486110994

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.